YT-002

YT-002 is a preclinical **small molecule** ischemia reperfusion injury candidate being developed by **Young Therapeutics** for myocardial infarction, acute kidney injury, organ transplantation, and stroke. Available company and contextual materials describe YT-002 as a **novel protein kinase C epsilon inhibitor** designed to provide cardioprotective and renoprotective effects when administered around reperfusion, with reported preclinical activity including reduction of infarct size, protection of cardiac function, and improvement of kidney function biomarkers in animal ischemia reperfusion models. The program appears to be positioned broadly for acute ischemic injury settings rather than a single chronic indication, and public information remains limited to preclinical and grant-supported development.